The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Regeneron Announces March 2012 Investor Conference Presentations

Tuesday, February 28, 2012

Regeneron Announces March 2012 Investor Conference Presentations16:05 EST Tuesday, February 28, 2012TARRYTOWN, N.Y., Feb. 28, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:Cowen and Company 32nd Annual Healthcare Conference at 10:40 a.m. Eastern Time on Tuesday, March 6, 2012 Barclays Capital 2012 Global Healthcare Conference at 3:45 p.m. Eastern Time on Wednesday, March 14, 2012The sessions may be accessed through the Company's web site, www.regeneron.com, on the Events and Presentations page.  Archived versions of the presentations will be available for thirty days after the live webcasts.  Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, one for the treatment of neovascular (wet) age-related macular degeneration and another for the treatment of a rare inflammatory condition.  Additionally, Regeneron has three regulatory applications pending before the U.S. Food and Drug Administration (FDA) and 10 drug candidates in clinical development.  More information and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:                                                                                    Manisha Narasimhan, Ph.D.                        Peter DworkinInvestor Relations                                       Corporate Communications                            914-847-5126                                             914.847.7640              manisha.narasimhan@regeneron.com peter.dworkin@regeneron.comSOURCE Regeneron Pharmaceuticals, Inc.